-
Represented Twill, Inc., a leader in digital-led care, in its sale to DarioHealth Corp. (NASDAQ: DRIO).
-
Represented Gain Therapeutics, Inc. (NASDAQ: GANX) in its $11 million public offering of common stock and pre-funded warrants. Titan Partners Groups acted as the sole bookrunning manager for the offering.
-
Represented Sonnet BioTherapeutics Holdings, Inc. in entering a ChEF Purchase Agreement with Chardan Capital Markets LLC related to an equity facility for the purchase of up to 5,000,000 shares of common stock for a maximum of $25,000,000 in aggregate gross proceeds.
-
Represented Piper Sandler (NYSE: PIPR) in its role as sole placement agent for the private placement of $100 million of common stock of Context Therapeutics Inc. (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors.
-
Represented Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) in their sale of $10 million of common stock and warrants to health-care focused institutional investors pursuant to a registered direct offering.
-
Represented Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company investigating REM-001 in an NIH-sponsored and funded open label study in cutaneous metastatic breast cancer, in its anticipated merger with TuHURA Biosciences, Inc. (“TuHURA”), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy.
-
Represented Corbus Pharmaceuticals Holdings, Inc. (NASAQ: CRBP) in its $150 million at-the-market offering.
-
Represented First Wave BioPharma, Inc. (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, in its $104 million acquisition of ImmunogenX, a clinical-stage biopharmaceutical company. The combined company will focus on advancing a GI pipeline comprised of multiple, late-stage clinical assets, including latiglutenase, a potentially first-in-class, near Phase 3-ready, targeted, oral biotherapeutic for celiac disease.
-
Represented Celldex Therapeutics, Inc. (NASDAQ: CLDX) in its $460.5 million public offering of common stock.
-
Represented Celldex Therapeutics, Inc. (NASDAQ: CLDX) in its at the market offering of up to $300.0 million of common stock.
-
Represented Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) in a $94.5 million public offering of common stock.
-
Represented Timber Pharmaceuticals, Inc. (NYSE: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, as special corporate counsel in connection with Timber’s voluntary petition for relief under Chapter 11 of the Bankruptcy Code and the sale of all of Timber’s assets to Leo Pharma A/S. The Bankruptcy Court approved the sale on January 22, 2024, and the transaction closed the same day.
-
Represented Coya Therapeutics, Inc. (Nasdaq: COYA), a clinical-stage biotechnology company developing proprietary therapies to enhance the function of regulatory T cells, in the closing of its private placement offering of 4,370,382 shares of its common stock for gross proceeds of approximately $26.5 million.
-
Represented Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, in its registered direct offering for gross proceeds of $30 million.
-
Representing Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a precision oncology company, in its exclusive [in-]licensing agreement with CSPC Megalith Biopharmaceutical Co., Ltd, a subsidiary of CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093), for the development and commercialization of CRB-701 (SYS6002), a novel clinical stage antibody drug conjugate (ADC) targeting Nectin-4.
-
Represented Artegraft, Inc., a processor and seller biologic vascular grafts derived from bovine carotid arteries and implanted primarily in hemodialysis access patients, in connection with the $90 million sale of its business and assets to LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of devices, implants and services for the treatment of peripheral vascular disease.
-
Represented Sonnet BioTherapeutics, Inc., a privately-held clinical stage biopharmaceutical company developing innovative targeted biologic drugs, in connection with its merger with Chanticleer Holdings, Inc. to form a company operating under the name Sonnet BioTherapeutics Holdings, Inc., with its shares trading on the Nasdaq Capital Market under the ticker symbol “SONN” and in connection with a private placement of $19 million and the acquisition of the global development rights for Atexakin Alfa from Relief Therapeutics SA.
